A study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 in Patients with Non-Muscle Invasive Bladder Cancer
The purposes of this research study are to find out the side effects of the study drug, ALT-803, plus BCG in Non-Muscle Invasive Bladder Cancer (NMIBC); find out how safe the study drug is and how well it is tolerated, and find out if the study drug plus Bacillus Calmette-Guerin (BCG) can stop the growth of the participant's tumor.
(1) Determination of MTD and designation of RD of ALT-803 in combination with BCG in patients who have non-muscle invasive bladder cancer (NMIBC).
(2) Safety profile of BCG+ALT-803 in treated patients.
(3) Disease response rate in treated patients.
(1) Immunogenicity and pharmacokinetic profiles of BCG+ALT-803 in treated patients.
(2) Molecular alterations (e.g., assessed by immunohistochemistry and antibody-based immunoassays) in collected tissues (e.g., bladder tissue, blood and urine) will be noted during therapy and compared to prior therapy.
(3) Recurrence-free survival, progression-free survival, overall survival, and duration of response of all treated patients.
Histologic confirmation of non-muscle invasive bladder cancer of the transitional cell carcinoma high-risk subtype. Patients are eligible if the diagnostic biopsy was done within 3 months (+ 2 week window) of treatment start and a cystoscopy demonstrates no gross disease within 4 weeks (+ 2 week window) of treatment start.
High risk is defined as any high-grade Ta or T1, CIS.
Currently eligible for intravesical BCG therapy (34,35) (i.e. BCG naïve).
Age ≥ 18 years.
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
Adequate laboratory test results within 14 days (+ 1 week window) of treatment start.
Adequate pulmonary function without any clinical sign of severe pulmonary dysfunction.
Negative serum pregnancy test if female and of childbearing potential.
Female participants of childbearing potential must adhere to using a medically accepted method of birth control prior to screening and agree to continue its use during the study or be surgically sterilized and males must agree to use barrier methods of birth control while on study.
Provide signed informed consent and HIPPA authorization and agree to comply with all protocol-specified procedures and follow-up evaluations.
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate buttonbelow. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub